Figure 2.

(a) Mean log‐scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase IIa study. (b) Mean log‐scaled concentrations of dupilumab in serum vs. nominal time: concentration–time profile of the phase III open‐label extension (OLE) study.
Horizontal arrows show timepoints of dupilumab administration. For both panels, concentrations below the limit of quantitation were set as LLOQ/2. LLOQ, lower limit of quantitation.